Himension Capital Singapore PTE. LTD. Invests $1.07 Million in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Himension Capital Singapore PTE. LTD. bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 4,529 shares of the biopharmaceutical company’s stock, valued at approximately $1,066,000.

Other institutional investors have also added to or reduced their stakes in the company. Quantbot Technologies LP raised its holdings in shares of Alnylam Pharmaceuticals by 1,754.5% during the 3rd quarter. Quantbot Technologies LP now owns 204 shares of the biopharmaceutical company’s stock valued at $56,000 after buying an additional 193 shares in the last quarter. Captrust Financial Advisors grew its position in Alnylam Pharmaceuticals by 34.4% during the third quarter. Captrust Financial Advisors now owns 4,833 shares of the biopharmaceutical company’s stock valued at $1,329,000 after acquiring an additional 1,237 shares during the last quarter. Quantinno Capital Management LP raised its stake in shares of Alnylam Pharmaceuticals by 50.3% during the third quarter. Quantinno Capital Management LP now owns 3,366 shares of the biopharmaceutical company’s stock worth $926,000 after acquiring an additional 1,126 shares in the last quarter. Kovitz Investment Group Partners LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $669,000. Finally, EP Wealth Advisors LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $201,000. Institutional investors own 92.97% of the company’s stock.

Insider Activity

In related news, Director Phillip A. Sharp sold 11,250 shares of the firm’s stock in a transaction that occurred on Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total transaction of $3,093,750.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the transaction, the executive vice president now directly owns 14,321 shares in the company, valued at $3,654,862.41. This trade represents a 4.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 71,234 shares of company stock worth $19,958,097 over the last three months. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Trading Down 10.1 %

NASDAQ:ALNY opened at $235.74 on Friday. The firm has a market capitalization of $30.67 billion, a P/E ratio of -108.64 and a beta of 0.30. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The company’s 50-day simple moving average is $259.03 and its 200 day simple moving average is $260.23.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analysts Set New Price Targets

ALNY has been the subject of several recent research reports. Scotiabank boosted their price target on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a “sector outperform” rating in a research note on Monday, March 31st. Redburn Atlantic assumed coverage on Alnylam Pharmaceuticals in a research note on Monday, March 31st. They issued a “buy” rating and a $353.00 target price for the company. Morgan Stanley increased their target price on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. Bank of America lifted their price target on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a “buy” rating in a research note on Friday, March 21st. Finally, Sanford C. Bernstein cut their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $316.25.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.